Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Estrella Immunopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Estrella Immunopharma, Inc.’s stock price such as:

• Estrella Immunopharma, Inc.’s current stock price and volume
• Why Estrella Immunopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for ESLA from analysts
• ESLA’s stock price momentum as measured by its relative strength

About Estrella Immunopharma, Inc. (ESLA)

Before we jump into Estrella Immunopharma, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Want to learn more about Estrella Immunopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Estrella Immunopharma, Inc..

Estrella Immunopharma, Inc.’s Stock Price as of Market Close

As of December 09, 2025, 4:00 PM, CST, Estrella Immunopharma, Inc.’s stock price was $2.120.

Estrella Immunopharma, Inc. is up 3.41% from its previous closing price of $2.050.

During the last market session, Estrella Immunopharma, Inc.’s stock traded between $1.901 and $2.160. Currently, there are approximately 37.10 million shares outstanding for Estrella Immunopharma, Inc..

Estrella Immunopharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Estrella Immunopharma, Inc. Stock Price History

Estrella Immunopharma, Inc.’s (ESLA) price is currently up 0.47% so far this month.

During the month of December, Estrella Immunopharma, Inc.’s stock price has reached a high of $2.200 and a low of $1.520.

Over the last year, Estrella Immunopharma, Inc. has hit prices as high as $3.150 and as low as $0.730. Year to date, Estrella Immunopharma, Inc.’s stock is up 76.67%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Estrella Immunopharma, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 09, 2025, there were analysts who downgraded Estrella Immunopharma, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Estrella Immunopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Estrella Immunopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Estrella Immunopharma, Inc. (ESLA) by visiting AAII Stock Evaluator.

Relative Price Strength of Estrella Immunopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 09, 2025, Estrella Immunopharma, Inc. has a weighted four-quarter relative price strength of 30.30%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Estrella Immunopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Estrella Immunopharma, Inc. Stock Price: Bottom Line

As of December 9, 2025, Estrella Immunopharma, Inc.’s stock price is $2.120, which is up 3.41% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Estrella Immunopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.